School of Medical Laboratory, Weifang Medical University, Weifang, Shandong, China.
Institutional Key Laboratory of Clinical Laboratory Diagnostics, 12th 5-Year Project of Shandong Province, Weifang Medical University, Weifang, Shandong, China.
Clin Transl Oncol. 2023 Aug;25(8):2297-2305. doi: 10.1007/s12094-023-03123-7. Epub 2023 Mar 1.
Pancreatic cancer is one of the deadliest types of cancer, with a death rate nearly equal to the incidence. The P2X7 receptor (P2X7R) is a kind of extracellular adenosine triphosphate (ATP)-gated ion channel with special permeability, which exists in most tissues of human body and mediates inflammation-related signaling pathways and immune signal transduction after activation. P2X7R is also present on the surface of several tumor cells and is involved in tumor growth and progression. P2X7R expression in pancreatic cancer has also been identified in recent studies. Activation of P2X7R in pancreatic cancer can support the proliferation of pancreatic stellate cells, participate in protein interactions, and mediate ERK1/2, IL-6/STAT3, hCAP-18/LL-37, PI3K/AKT signaling pathways to promote pancreatic cancer progression. Inhibitors targeting P2X7R can inhibit the development of pancreatic cancer and are expected to be used in clinical therapy. Therefore, P2X7R is promising as a potential therapeutic target for pancreatic cancer. This article reviews the progress of research on P2X7R in pancreatic cancer.
胰腺癌是致死率最高的癌症之一，其死亡率几乎与发病率持平。P2X7 受体（P2X7R）是一种细胞外三磷酸腺苷（ATP）门控离子通道，具有特殊的通透性，存在于人体大多数组织中，在激活后介导炎症相关信号通路和免疫信号转导。P2X7R 也存在于几种肿瘤细胞的表面，并参与肿瘤的生长和进展。最近的研究也确定了胰腺癌中 P2X7R 的表达。在胰腺癌中激活 P2X7R 可以支持胰腺星状细胞的增殖，参与蛋白质相互作用，并介导 ERK1/2、IL-6/STAT3、hCAP-18/LL-37、PI3K/AKT 信号通路，促进胰腺癌的进展。靶向 P2X7R 的抑制剂可以抑制胰腺癌的发展，有望用于临床治疗。因此，P2X7R 有望成为胰腺癌的潜在治疗靶点。本文综述了 P2X7R 在胰腺癌中的研究进展。
